Compare LMT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMT | SNY |
|---|---|---|
| Founded | 1912 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | LMT | SNY |
|---|---|---|
| Price | $456.25 | $49.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $518.79 | $61.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 10-21-2025 | 10-24-2025 |
| Dividend Yield | 3.01% | ★ 3.21% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | ★ 17.88 | 8.67 |
| Revenue | ★ $73,349,000,000.00 | $53,890,648,839.00 |
| Revenue This Year | $5.97 | $2.37 |
| Revenue Next Year | $4.24 | $6.51 |
| P/E Ratio | $25.60 | ★ $11.32 |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $410.11 | $44.62 |
| 52 Week High | $529.48 | $60.12 |
| Indicator | LMT | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 48.29 |
| Support Level | $448.48 | $49.14 |
| Resistance Level | $457.26 | $50.61 |
| Average True Range (ATR) | 8.09 | 0.76 |
| MACD | -0.65 | -0.18 |
| Stochastic Oscillator | 21.28 | 28.73 |
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.